Lowers the risk of cardiovascular death and hospitalization for heart failure. ANDA 213680, held by Biocon Pharma. Sacubitril; Valsartan.
As of Nov 19, 2026, ANDA 213680 (Sacubitril and Valsartan), held by Biocon Pharma, was first approved by FDA on Aug 30, 2024, with 0 approved supplements and 0 published complete response letters.
Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and are indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2024 | Original application | Approved | None posted |
| Sacubitril and Valsartan24MG;26MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan49MG;51MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan97MG;103MG · tablet;oral | Sacubitril; Valsartan | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters